GlassScriptPhysician profile
Kimberlee Davis
NPI 1265581938
$1,634.25
in general payments reported to CMS, 2019-2025
24 companies · $37.28 in 2025
The $37.28 reported for 2025 was less than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $312 · 2023: $566 · 2024: $615 · 2025: $37.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,218.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $227.12 | 2023-2024 | Veozah, Myrbetriq, Vesicare |
| Novartis Pharmaceuticals Corporation | $215.85 | 2022-2025 | |
| Lilly USA, LLC | $185.89 | 2021-2024 | Mounjaro |
| Galderma Laboratories, L.P. | $112.02 | 2024 | |
| Abbvie INC. | $97.11 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $95.72 | 2022-2024 | Breztri, Flumist Quadrivalent, Airsupra |
| Novo Nordisk INC | $86.34 | 2021-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $84.53 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.49 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.26 | 2021-2024 | Jardiance |
| Exact Sciences Corporation | $66.16 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $50.51 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $37.08 | 2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $33.32 | 2023 | Quviviq |
| Tactile Systems Technology INC | $32.74 | 2023 | Flexitouch Plus, Entre Plus |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.96 | 2023-2024 | Otezla, Repatha |
| Corium, LLC | $20.10 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.32 | 2024 | Nuzyra |
| Sumitomo Pharma America, INC. | $17.22 | 2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $15.60 | 2021 | |
| Lundbeck LLC | $15.17 | 2024 | Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $14.78 | 2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.75 | 2024 | Xifaxan |
| Genentech USA, INC. | $8.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberlee Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.